Inhaled gene therapy for cystic fibrosis enters the clinic
Boehringer Ingelheim, IP Group, the UK Respiratory Gene Therapy Consortium (GTC) and OXB have announced the start of LENTICLAIR 1, a Phase I/II trial of gene therapy BI 3720931.
The therapy has been designed to improve disease outcomes in people with cystic fibrosis (CF), regardless of gene mutations that are causing the disease.
The trial specifically focuses on adults with CF who genetically cannot benefit from CF transmembrane conductance regulator (CFTR) modulators.
CF is caused by mutations in the CFTR gene that cause the CFTR protein to become dysfunctional, which leads to the development of sticky, thick mucus clogging the airways.
This causes long-lasting lung infections that increasingly limit the person’s ability to breathe.
More than 2,000 known mutations of this gene lead to different levels of severity of the disease, depending on the specific mutations that have occurred.
Treatment with CFTR modulators, which target the underlying defects in the CFTR protein, has brought progress for people with specific mutations. Unfortunately, these treatments are not suitable for 10-15% of people with CF, either because of their mutation type or due to intolerance of modulators.
“We are very excited about the start of the LENTICLAIR 1 First-In-Human trial and how BI 3720931 could potentially improve the lives of people living with CF, and who are unable to benefit from current CFTR modulators,” said Dr Paola Casarosa, Member of the Board of Managing Directors at Boehringer Ingelheim with responsibility for the Innovation Unit.
“The partnership with the GTC and OXB provides an excellent example of the progress that can be made when diverse organisations and people come together with a long-term, shared goal to create a new paradigm of care.”
A lentiviral vector-based gene therapy
BI 3720931 is a first-in-class, inhaled lentiviral vector-based gene therapy that could potentially address unmet needs by inserting a functional copy of the CFTR gene in the DNA of airway epithelial cells.
The aim is to improve lung function and reduce exacerbations for people with CF irrespective of their mutations, including those who genetically cannot benefit from CFTR modulators.
Professor Eric Alton of Imperial College London’s National Heart and Lung Institute, who coordinates the GTC, added: “The GTC is very excited to have reached this milestone after 24 years of focused effort and in close collaboration with our partners and people with CF. While the immediate target are those adult patients who are not eligible for CFTR modulators, this novel therapy has the potential to achieve long-lasting CFTR function improvement and disease modification for people with CF irrespective of mutation type and has the potential for re-dosing if needed.”
The trial is expected to be completed in early 2027.
Diana Spencer, Senior Digital Content Editor, DDW
